Skip to main content
SpringerLink
Log in

Genetic Mapping and Tailored Antihypertensive Therapy

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

A tailored or individualized antihypertensive therapy represents the new frontier for the treatment of essential hypertension and its organ complications. Indeed, individual variation in the efficacy and tolerability of antihypertensive drugs in human essential hypertension is currently experienced by all physicians and is linked to the genetic heterogeneity of this multifactorial disease. Different approaches have been pursued in the attempt to correlate specific responsiveness to the therapy with phenotypic traits of the patients, but with poor results. More recently, the genetic approach to the study of the mechanisms underlying hypertension has led to the identification of some quantitative trait loci or genes that influence blood pressure both in animal models and in patients.

But the relevance of these polymorphisms for defining and classifying patients in terms of therapy responsiveness must be analyzed in a more complex context that takes into account the crucial aspects of environmental influences, stage of disease, previous treatments, efficacy, tolerance, and duration of the treatment. Only a few examples of a pharmacogenomic approach to hypertension therapy are now available. In particular, the association of different variants of ACE, angiotensinogen, and G-protein genes with the blood pressure response to drugs interfering with RAS or β-adrenergic receptor has been studied. However, the results of these studies cannot be considered conclusive, since not all the criteria have been fully applied for proper assessment of an association between genetic polymorphism and drug response. Our group has identified a polymorphism of the genes coding for the cytoskeletal protein, adducin, which is associated with both rat and human hypertension, sodium sensitivity, and the antihypertensive effects of diuretics. A modification of the renal Na–KATPase leading to an increase of tubular sodium reabsorption seems to be the most likely underlying mechanism. A new antihypertensive compound has been developed that can correct the abnormality of the renal Na–KATPase and the blood pressure increase associated with adducin polymorphism in the rat. At present, the antihypertensive activity of this compound is under evaluation in patients with different adducin genotypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996;272:676-680.

    Google Scholar 

  2. Horan MJ, Mockrin SC. Heterogeneity of hypertension. Am J Hypertens 1992;5:110S-113S.

    Google Scholar 

  3. Hamet P, Pausova Z, Adarichev V, Adaricheva K, Tremblay J. Hypertension: genes and environment. J Hypertens 1998;16:397-418.

    Google Scholar 

  4. Sever P. The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? J Cardiovasc Pharmacol 1998;31 (Suppl 2):S1-S84.

    Google Scholar 

  5. Niutta E, Cusi D, Colombo R, et al. Predicting interindividual variation in anti-hypertensive therapy: the role of sodium transport systems and renin. J Hypertens 1990;6(Suppl 4):S53-S58.

    Google Scholar 

  6. Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988;12:223-226.

    Google Scholar 

  7. Menard J, Bellet M, Serrurier D. From the parallel group study to the crossover design, and from the group approach to the individual approach. Am J Hypertens 1990;3:815-819.

    Google Scholar 

  8. Pratt RE, Dzau VJ. Genomics and hypertension. Concepts, potentials and opportunities. Hypertension 1999;33:238-247.

    Google Scholar 

  9. SoRelle R. New rules for high blood pressure. Circulation 1998;97:307-308

    Google Scholar 

  10. Berlowitz DR, Ash AA, Hichey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-1963.

    Google Scholar 

  11. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet 1997;349:454-457.

    Google Scholar 

  12. Weber MA. Unsolved problems in treating hypertension. Rationale for new approaches. Am J Hypertens 1998;11: 145S-149S.

    Google Scholar 

  13. Ferrari P. Pharmacogenomics: a new approach to individual therapy of hypertension? Curr Opin Nephrol Hypertens 1998;7:217-222.

    Google Scholar 

  14. Luft FC. Molecular genetics of human hypertension. J Hypertens 1998;16:1871-1878.

    Google Scholar 

  15. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, Diagnosis and Management. New York: Raven Press, 1995:67-88.

    Google Scholar 

  16. Rapp JP. The search for the genetic basis of blood pressure variation in rats. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 1995:1289-1300.

    Google Scholar 

  17. Bianchi G, Tenconi T, Lucca R. Effect in the conscious dog in constriction of the renal artery to a sole remaining kidney on haemodynamics, sodium balance, body fluid volumes, plasma renin concentration and pressor responsiveness to angiotensin. Clin Sci 1970;38:741-766.

    Google Scholar 

  18. Watkins BE, Davis JM, Freeman RH, De Forrest JM, Stephens GA. Continuous angiotensin II blockade throughout the acute phase of one-kidney hypertension in dog. Circ Res 1978;42:813-820.

    Google Scholar 

  19. Freeman RH, Davis JO, Watkins BE, Stephens GA, De Forrest JM. Effects of continuous converting enzyme blockade on renovascular hypertension in the rat. Am J Physiol 1979;236(1):F21-24.

    Google Scholar 

  20. Edmunds ME, Russel GI, Bing RF. Reversal of experimental renovascular hypertension. J Hypertens 1991;9:289-301.

    Google Scholar 

  21. Bianchi G, Baer PG, Fox U, Duzzi L, Pagetti D, Giovanetti AM. Changes in renin, water balance and sodium balance during development of high blood pressure in genetically hypertensive rats. Circ Res 1975;36,37(Suppl 1):153-161.

    Google Scholar 

  22. Lund-Johansen P, Omvik P. Hemodynamic patterns of untreated hypertensive disease. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, Diagnosis and Management. New York: Raven Press, 1995:305-327.

    Google Scholar 

  23. Guyton AC, Hall JE, Coleman TG, Manning RD, Norman RA. The dominant role of the kidneys in long-term arterial pressure regulation in normal and hypertensive states. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 1995:1311-1326.

    Google Scholar 

  24. Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertensives after withdrawal of long-term antihypertensive treatment. Br Med J 1986;293:988-992.

    Google Scholar 

  25. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Return of elevated blood pressure after withdrawal of antihypertensive drugs. Circulation 1975;51:1107-1113.

    Google Scholar 

  26. Swart S, Bing RF, Swales JD, Thurston H. Plasma renin in long-term diuretic treatment of hypertension: effect of discontinuation and restarting therapy. Clin Sci 1982;63:121-125.

    Google Scholar 

  27. Boyle RM, Price ML, Hamilton M. Thiazide withdrawl in hypertension. J R Coll Physicians Lond 1979;13:172-173.

    Google Scholar 

  28. Lowder SC, Liddle GW. Prolonged alteration of renin responsiveness after spironolactone therapy. N Engl J Med 1974;291:1243-1244.

    Google Scholar 

  29. Marshall A. Getting the right drug into the right patient. Nature Biotech 1997;15:1249-1252.

    Google Scholar 

  30. Housman D, Ledley FD. Why pharmacogenomics? Why now? Nature Biotech 1998;16:492-493.

    Google Scholar 

  31. Jick H, Garcia Rodriguez LA, Perez-Gutthan S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998;352:1767-1770.

    Google Scholar 

  32. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliff P. Prediction of patient responses to antihypertensive drugs using genetic polymorphism: investigation of renin-angiotensin system genes. J Hypertens 1996;14:259-262.

    Google Scholar 

  33. Hingorani AD, Jia H, Stevens Pa, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995;13:1602-1609.

    Google Scholar 

  34. Hunt SC, Cook NR, Oberman A, et al. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension. Hypertension 1998;32:393-401.

    Google Scholar 

  35. O'Toole L, Steward M, Padfield P, Canner K. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998;32:988-994.

    Google Scholar 

  36. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.

    Google Scholar 

  37. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: result of the Survival and Left Ventricular Enlargement Trial. N Engl J Med 1992;327:669-677.

    Google Scholar 

  38. Vincent M, Samani NJ, Gauguier D, Thompson JR, Lathrop MG, Sassard J. A pharmacogenetic approach to blood pressure in Lyon hypertensive rats. A chromosome 2 locus influences the response to a calcium antagonist. J Clin Invest 1997;100:2000-2006.

    Google Scholar 

  39. Barber BR, Ferrari P, Bianchi G. The Milan hypertensive strain: a description of the model. In: Ganten D, de Jong W, eds. Handbook of Hypertension. Amsterdam: Elsevier, 1994:316-345.

    Google Scholar 

  40. Ferrari P, Bianchi G. Lessons from experimental genetic hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press 1995;1261-1280.

    Google Scholar 

  41. Bianchi G, Baer PG, Fox U, Duzzi L, Pagetti D, Giovanetti AM. Changes in renin, water balance and sodium balance during development of high blood pressure in genetically hypertensive rats. Circ Res 1975;36,37 (Suppl 1):153-161.

    Google Scholar 

  42. Ferrandi M, Tripodi G, Salardi S, et al. Renal Na-KATPase in genetic hypertension. Hypertension 1996;28:1018-1025.

    Google Scholar 

  43. Salardi S, Saccardo B, Borsani G, et al. Erythrocyte adducin differential properties in normotensive and hypertensive rats of the Milan Strain (characterization of spleen adducin m-RNA). Am J Hypertens 1989;2, 4:229-237.

    Google Scholar 

  44. Hughes CA, Bennett V. Adducin: a physical model with implications for function in assembly of spectrin-actin complexes. J Biol Chem 1995;270:18990-18996.

    Google Scholar 

  45. Matsuoka Y, Hughes CA, Bennet V. Definition of the calmodulin-binding domain and sites of phosphorylation by protein kinase A and C. J Biol Chem 1996;271:25157-25166.

    Google Scholar 

  46. Bianchi G, Tripodi G, Casari G, et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 1994;91:3999-4003.

    Google Scholar 

  47. Tripodi G, Valtorta F, Torielli L, et al. Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 1996;97:2815-2822.

    Google Scholar 

  48. Ferrandi M, Salardi S, Tripodi G, Barassi P, Rivera R, Manunta P, Goldshlager R, Ferrari P, Bianchi G, Karlish S. Interaction between Adducin and Na-KATPase. Differential effect of hypertension related human and rat Adducin polymorphisms. Am J Physiol 1999;277:H1338-H1349.

    Google Scholar 

  49. Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G, Ferrari P. Ouabainlike factor in Milan hypertensive rats. Am J Physiol 1992;263:F739-F748.

    Google Scholar 

  50. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 1997;30:886-896.

    Google Scholar 

  51. Casari G, Barlassina C, Cusi D. Association of the α-adducin locus with essential hypertension. Hypertension 1995;25:320-326.

    Google Scholar 

  52. Cusi D, Barlassina C, Azzani T, et al. Polymorphism of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349:1353-1357.

    Google Scholar 

  53. Castellano M, Barlassina C, Muiesan ML, et al. Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general population. J Hypertens 1997;15:1707-1710.

    Google Scholar 

  54. Iwai N, Tamaki S, Nakamura Y, Kinoshita M. Polymorphism of α-adducin and hypertension. Lancet 1997;350:369.

    Google Scholar 

  55. Ishikawa K, Katsuya T, Sato N, et al. No association between a-adducin 460 polymorphism and essential hypertension in a Japanese population. Am J Hypertens 1998;11:502-506.

    Google Scholar 

  56. Kato N, Sugiyama T, Nabika T, et al. Lack of association between the alpha-adducin locus and essential hypertension in the Japanese population. Hypertension 1998;31:730-733.

    Google Scholar 

  57. Glorioso N, Manunta P, Filigheddu F, et al. The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999, in press.

  58. Ferrari P, Torielli L, Ferrandi M, et al. PST228: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharm Exp Ther 1998;285:83-94.

    Google Scholar 

  59. Ferrari P, Ferrandi M, Torielli L, Tripodi G, Melloni P, Bianchi G. PST 2238: a new antihypertensive compound that modulates Na-KATPase and antagonizes the pressor effect of OLF. Cardiovasc Drug Rev 1999, in press.

  60. Quadri L, Bianchi G, Cerri A, et al. 17β-(3-Furyl)-5β-androstane-3β,14β,17α-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem 1997;40:1561-1564.

    Google Scholar 

  61. Ferrari P, Ferrandi M, Tripodi G, et al. PST 228: a new antihypertensive compound that modulates Na-KATPase in genetic hypertension. J Pharm Exp Ther 1999;288:1074-1083.

    Google Scholar 

  62. Tripodi G, Szpirer C, Reina C, Szpirer J, Bianchi G. Polymorphism of adducin gene in genetic hypertension and mapping of the gene to rat chromosome 1q55. Biochem Biophys Res Commun 1997;237:685-689.

    Google Scholar 

  63. Nguyen AT, Hayward-Lester A, Sabatini S, Doris PA. Renal Na-KATPase in SHR: studies of activity and gene expression. Clin Exp Hypertens 1998;20(5&6):641-656.

    Google Scholar 

  64. Doris PA. Ouabain in plasma from spontaneously hypertensive rats. Am J Physiol 1994;266:H360-H364.

    Google Scholar 

  65. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nature Genet 1999;21:48-50.

    Google Scholar 

  66. Wang X, Feuerstein GZ. The use of mRNA differential display for discovery of novel therapeutic targets in cardiovascular disease. Cardiovasc Res 1997;35:414-421.

    Google Scholar 

  67. Barlassina C, Nicholas J, Schork P, Manunta P, Citterio L, Sciarrone MT, Lanella G, Bianchi G, Cusi D. Synergistic effect of α-adducin and ACE genes in causing blood pressure changes with body sodium and volume expansion, Kidney Int. 2000 in press.

Download references

Author information

Authors and Affiliations

  1. PRASSIS Research Institute Sigma-Tau (P.F.), Milan, Italy

    Patrizia Ferrari

  2. Division of Nephrology and Hypertension, University of Milan and S. Raffaele Hospital (G.B.), Milan, Italy

    Giuseppe Bianchi

Authors
  1. Patrizia Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Bianchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferrari, P., Bianchi, G. Genetic Mapping and Tailored Antihypertensive Therapy. Cardiovasc Drugs Ther 14, 387–395 (2000). https://doi.org/10.1023/A:1007860115489

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007860115489

Search

Navigation